With the rise and evolution of several targeted approaches to examine prostate cancer using PSMA, the aim of this contribution is to review the current role of PSMA as a marker for PCa diagnosis, imaging, and therapy. This evidence concerns the gene FOLH1 and prostate carcinoma.